Caplin Point Laboratories

1. Caplin Plant I (CP1) Strategic Growth Initiatives:

• Location: Suthukeny, Puducherry
• Product: Softgel
• Target Market: Existing Markets
• Status: Completed in Q4 FY23

2. Caplin Steriles Phase II (CP4):

• Location: Gummidipoondi, Chennai
• Products: Injectable Vials and Pre-Filled Syringes
• Target Market: Regulated Markets
• Status: Line 5 commissioned in Oct ’23; Line 6 qualification ongoing
• Timeline: Line 6 expected to be qualified by Q4 FY24

3. API Facility:

• Location: Visakhapatnam, Andhra Pradesh
• Products: General API
• Target Market: Existing and Regulated Markets
• Status: Ongoing
• Timeline: Expected to be completed by Q4 FY24

4. Oncology Facility:

• Location: SIDCO, Kakkalur (Near Chennai)
• Products: OSD & Injectable
• Target Market: Existing and Regulated Markets
• Status: Ongoing
• Timeline: OSD production is expected to start in Q3 FY24, and Injectable production is anticipated in Q2 FY25

5. Oncology API Facility:

• Location: SIDCO, Kakkalur, Near Chennai
• Product: Oncology API
• Target Market: Existing and Regulated Markets
• Status: Commencing shortly
• Timeline: Expected to start in Q2 FY25

6. OSD Facility:

• Location: Thervoy SIPCOT, Chennai
• Product: Oral Solid Dosages
• Target Market: Existing Market, including Mexico, Brazil, US, and EU
• Status: Commencing shortly
• Timeline: Expected to start in Q3 FY25

Caplin Point has allocated a total Capex budget of approximately ₹600-650 Crores for these investment projects. These initiatives aim to enhance production capacities, expand the product range, and achieve backward integration for various products. Importantly, the company plans to fund the Capex through internal accruals, ensuring that it maintains a net positive cash position throughout the process.

The locations of these plants and facilities are distributed across Tamil Nadu and Andhra Pradesh, India, demonstrating Caplin Point’s commitment to meeting market demands and expanding its operational footprint.